CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. (SZSE: 000908)
Health Care · Pharmaceuticals · CN
CN¥6.69
-3.74% today · +16.6% 1Y
CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. (SZSE: 000908) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $1.75B and employs 463 people.
Over the last twelve months the share price has gained 16.6%, trading between 4.58 and 9.48.
Tweenvest scores CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. across four factors: quality 57/100, value 36/100, growth 0/100. Its strongest factor is quality.
000908 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.75B
- Revenue (TTM)
- $58.46M
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- -0.16
- 52-week high
- CN¥9.48
- 52-week low
- CN¥4.58
- Avg volume (3M)
- —
- Shares outstanding
- 1.76B
- Employees
- 463
- Next earnings
- —
About CSPC Hunan Jingfeng Pharmaceutical Co., Ltd.
Hunan Jingfeng Pharmaceutical Co.,Ltd., established in 2003 and headquartered in Shanghai, China, operates as a manufacturer and supplier of various pharmaceutical products, including chemical compounds and biological agents, within the Chinese market. A prominent offering from the company is its sodium hyaluronate injection, which finds extensive application in both orthopedic and surgical fields. Beyond this, their product range encompasses ophthalmology solutions and Active Pharmaceutical Ingredients (APIs). The firm also dedicates resources to the research and development of medications for anti-tumor, cancer, and cardiovascular conditions, alongside providing a selection of skincare products.
- ISIN
- CNE000000Y11
- Founded
- 1998
- Listed since
- Feb 3, 1999
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.